Real-world experience with efgartigimod in generalized myasthenia gravis: a single-center retrospective study in China
Zhenyu Niu·Haiqiang Jin·Jingru Ren·Liu R·J Z Guo·Nan Zhang·Yiming Zheng·Hongjun Hao·Feng Gao·Jianchun Wang
Objective This study aimed to evaluate the real-world efficacy, safety, and application patterns of efgartigimod in Chinese patients with generalized myasthenia gravis (gMG), with a focus on individualized treatment strategies. Methods We conducted a single-center, retrospective analysis of 81 gMG patients who received at least one standard cycle of efgartigimod (10 mg/kg weekly for 4 weeks). Disease severity was assessed using Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative